Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in ...
Patients with Crohn disease report high satisfaction and minimal discomfort using the citrate-free biosimilar CT-P17, enhancing adherence to treatment.
New research reveals that switching from originator to biosimilar adalimumab for hidradenitis suppurativa may lead to reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback